Stephens reaffirmed their overweight rating on shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in a research report released on Tuesday morning. Stephens currently has a $19.00 price objective on the medical instruments supplier’s stock, up from their previous price objective of $14.00.
OSUR has been the subject of a number of other research reports. Jefferies Group LLC boosted their price target on OraSure Technologies from $12.00 to $16.00 and gave the company a buy rating in a report on Thursday, May 4th. Zacks Investment Research lowered OraSure Technologies from a buy rating to a hold rating in a report on Wednesday, April 12th. Finally, Canaccord Genuity boosted their price target on OraSure Technologies from $15.00 to $18.00 and gave the company a buy rating in a report on Wednesday, June 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $14.89.
Shares of OraSure Technologies (OSUR) opened at 19.01 on Tuesday. The firm has a 50-day moving average price of $15.30 and a 200 day moving average price of $12.00. OraSure Technologies has a 12-month low of $6.23 and a 12-month high of $19.05. The stock has a market cap of $1.10 billion, a PE ratio of 36.42 and a beta of 1.56.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.04. The business had revenue of $32.55 million during the quarter, compared to analyst estimates of $31.19 million. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.04 earnings per share. Equities research analysts expect that OraSure Technologies will post $0.43 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2722280/orasure-technologies-inc-osur-earns-overweight-rating-from-stephens.html.
In other OraSure Technologies news, SVP Mark L. Kuna sold 36,413 shares of the company’s stock in a transaction on Monday, May 8th. The stock was sold at an average price of $15.11, for a total transaction of $550,200.43. Following the completion of the sale, the senior vice president now owns 92,904 shares in the company, valued at $1,403,779.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Douglas A. Michels sold 290,495 shares of the company’s stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total value of $4,865,791.25. Following the sale, the chief executive officer now owns 894,012 shares of the company’s stock, valued at approximately $14,974,701. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,220,134 shares of company stock valued at $18,789,795. 7.80% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Eqis Capital Management Inc. bought a new stake in OraSure Technologies during the second quarter worth $371,000. State of Alaska Department of Revenue raised its stake in OraSure Technologies by 85.1% in the second quarter. State of Alaska Department of Revenue now owns 11,401 shares of the medical instruments supplier’s stock worth $196,000 after buying an additional 5,241 shares in the last quarter. Fisher Asset Management LLC raised its stake in OraSure Technologies by 35.5% in the second quarter. Fisher Asset Management LLC now owns 682,480 shares of the medical instruments supplier’s stock worth $11,780,000 after buying an additional 178,886 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new stake in OraSure Technologies during the second quarter worth $329,000. Finally, Bank of Montreal Can raised its stake in OraSure Technologies by 102.8% in the second quarter. Bank of Montreal Can now owns 143,295 shares of the medical instruments supplier’s stock worth $2,472,000 after buying an additional 72,644 shares in the last quarter. Institutional investors own 88.23% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.